Recom Names J&J Veteran Pamela Bunes as President.

LOS ANGELES -- Recom Managed Systems, Inc. (OTCBB:RECM), a life-sciences company developing patented heart-monitoring technology, today announced that Pamela Bunes, a veteran of the healthcare industry, has been appointed Chief Executive Officer and President. Ms. Bunes accepted a five-year tenure on Recom's Board of Directors last month. She was also acting as a consultant to the company. Dr. Lowell Harmison, former Principal Deputy of the United States Department of Health Services, will continue in his important administrative and creative roles both as a consultant and as a director of the company and will also continue to assist Ms. Bunes as Recom's co-Chief Executive Officer throughout the period of transition.

Terms of Ms. Bunes' contract with Recom have been approved by the Board of Directors but have not yet been disclosed.

"Pamela's impressive experience in the medical device industry well-positions her to lead Recom through the critical months ahead, as the organization prepares for the commercialization of the Model 100 Heart Monitor," said Lucy Duncan-Scheman, chairperson of the board of Recom. "I am confident that under Pamela's leadership, Recom will fulfill its promise in providing cardiac-care practitioners the most sophisticated and effective long-term ECG solution ever developed."

Ms. Bunes' appointment as Chief Executive Officer and President is the latest step taken to better position the company as it shifts towards a focus on marketing its proprietary technology. The company secured $8 million in two rounds of private-placement financing earlier this month that will be used in large part to support commercialization of the Model 100 Heart Monitor 12-lead electrocardiograph (ECG) technology, which utilizes a patented signal-processing platform to allow for the production and recording of a clinical-quality ECG while the patient is ambulatory.

Recom's proprietary technology is currently being evaluated at Duke Clinical Research Institute (DCRI) in Durham, N.C. The double-blinded, 100-patient DIVA trial will establish the performance of Recom's device against the current standard of care in ambulatory cardiac-monitoring technology. Results from DIVA, which is being led by Mitchell W. Krucoff, MD, director of the Ischemia Monitoring Lab and Interventional Devices Clinical Trials at DCRI, associate professor of medicine at Duke Medical Center, and director of the Cardiovascular Laboratory at the Durham Veterans Affairs Medical Center, are expected in the third quarter of 2005. Two additional studies at Duke are in the planning stages.

"I am excited to have the opportunity to guide Recom as we enter this new era and to lead its evolution from a research-and-development organization into an innovator in the marketing of superior ECG technology, which has the potential to revolutionize the diagnostic care of cardiac patients," Ms. Bunes said.

Ms. Bunes most recently was employed by Biosense Webster, Inc., a subsidiary of Johnson & Johnson. Prior to that, she served as executive account manager with Ethicon Endo-Surgery, Inc. (another JNJ subsidiary), where she started as account manager in October 1990. Biosense Webster and Ethicon Endo-Surgery are valued subsidiaries of Johnson & Johnson. Previously, Ms. Bunes held numerous positions, including vice president of First Union National Bank. Ms. Bunes has a bachelor of arts degree with double majors in economics and business administration (finance) from Converse College in Spartanburg, S.C.

Breakthrough ECG Monitoring Technology

Recom's first product, the Model 100 Heart Monitor, is an ambulatory patient heart monitor that uses patented signal-processing technology to record a clinical-quality ECG signal in the presence of "noise," or interference, generated by the patient's body movements and ambient environment. By reducing these interfering factors during recordings, the Recom Model 100 helps general practitioners and cardiologists more accurately detect cardiac abnormalities or changes that may occur during daily activities and allows medical experts to collect extensive, continuous cardiac data over time, which can establish a baseline against which future readings can be compared. The Model 100 provides up to 48 hours of real-time heart monitoring during patients' everyday activities. The Model 100 has received 510(k) clearance from the Food and Drug Administration (FDA).

About Recom Managed Systems, Inc.

Recom Managed Systems, Inc. is an emerging life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Recom Managed Systems, Inc. uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. With our patented signal-technology platform, Recom brings clinical-quality physiological signal monitoring to the ambulatory setting.

Recom Managed Systems, Inc. is traded on the OTC Bulletin Board under the symbol RECM.OB. More information is located at http://www.recom-systems.com.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Recom's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approvals governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Recom's products or services, adverse equity-market conditions and declines in the value of Recom's common stock, and the unavailability of financing to complete management's plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Recom's filings with the Securities and Exchange Commission.